ArticleInternational journal of hematology2022

A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).

Hideki Nakayama et al.PubMed ↗Publisher ↗

No numbers read from the abstract.